Mark Coles

Co-founder @Mestag Therapeutics

Oxford, GB
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

May 2020 — Present

Co-founder @Mestag Therapeutics

View department →

London, GB

Mestag Therapeutics is a fast-moving, stealth mode biotech, newly formed to explore emerging understanding of fibroblast subpopulations as targetable drivers of disease. Our goal is to bring transformative therapies to enriched patient populations with enduring unmet needs in inflammatory disease and oncology. Mestag Therapeutics’ founders are world leaders in fibroblast biology and severe diseases. We are actively assembling a driven, motivated team to explore new therapeutic opportunities. Backed by SV Health Investors, a leading life sciences & healthcare investor with over $3 billion in capital commitments, Mestag has raised capital from the Impact Medicine Fund, which invests in precision medicine therapeutics in areas of high unmet need.

EDUCATION

1992 — 1998

University of California, Berkeley

Doctor of Philosophy (Ph.D.), Molecular Cell Biology

1988 — 1992

Cornell University

Bachelor’s Degree, Microbiology, General

SKILLS

Cell CultureScienceCell BiologyMolecular BiologyBiochemistryResearchFlow CytometryCancerPcrConfocal MicroscopyCellMicroscopyTissue CultureImmunologyLife Sciences

ABOUT MARK COLES

Research in the Stromal and Systems Immunology Group at the Kennedy Institute of…

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Mark Coles — Co-founder at Mestag Therapeutics in Oxford, GB | Unifers